Gujarat-based manufacturer of pharmaceutical products, operating a single factory and application lab after demerging its Aromatic Chemicals (Diphenyl Oxide) business in 2024.
Price
Market Cap
Sector
Commodities
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 6 | 6 | 6 | 31 | 31 | 31 | 31 | 31 |
| Reserves | 48 | 59 | 67 | 58 | 82 | 90 | 106 | 126 |
| Borrowings | 6 | 10 | 15 | 19 | 7 | 6 | 2 | 5 |
| Other Liabilities | 13 | 16 | 16 | 19 | 22 | 18 | 26 | 26 |
| Total Liabilities | 73 | 92 | 104 | 127 | 143 | 146 | 165 | 188 |
| AssetsFixed Assets | 34 | 32 | 53 | 61 | 61 | 45 | 48 | 57 |
| CWIP | 6 | 18 | 0 | 0 | 1 | 0 | 5 | 0 |
| Investments | 1 | 10 | 11 | 11 | 15 | 0 | 6 | 20 |
| Other Assets | 32 | 32 | 40 | 55 | 65 | 101 | 105 | 110 |
| Total Assets | 73 | 92 | 104 | 127 | 143 | 146 | 165 | 188 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 4 | 13 | 15 | 6 | 13 | 23 | 24 | 52 |
| Cash from Investing | -2 | -10 | -19 | -7 | -13 | -9 | -22 | -41 |
| Cash from Financing | 1 | -4 | 3 | 3 | 1 | -14 | -4 | -5 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 2 | 4 | 4 | -1 | 0 | 17 | -16 | 42 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (16.8×) and current (19.3×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 34.4% growth and a 17× exit, ₹232 only delivers your return if you pay ₹430. The price is currently baking in 20% growth.
EPS grows 34.4%/yr for 5 years, then fades to 6% over 2, exits at 17×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 34.4% | 16.18 |
| FY28 | 34.4% | 21.75 |
| FY29 | 34.4% | 29.23 |
| FY30 | 34.4% | 39.28 |
| FY31 | 34.4% | 52.80 |
| FY32 | 20.2% ·fade | 63.46 |
| FY33 | 6.0% ·fade | 67.27 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.